Boston Globe Runs "Middle Road" Editorial on Biologics Issue

The Boston Globe covered the follow-on biologics (also called generic biologics) issue in a "middle road" editorial this week. It appropriately supports a regulatory pathway to safe, effective, comparable versions of costly biologic drugs for people living with MS and other diseases who need them. At the same time, it supports the need for competition in encouraging innovation. Click here to read the full editorial.